drugset / Trial / NCT00078260

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

NCT00078260

Phase 3 Completed 589 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are to determine: * the safety of pemetrexed and any side effects that might be associated with it * how much pemetrexed should be given to patients. It is possible that information collected during this study will be analyzed by the Sponsor in the future to evaluate pemetrexed for other possible uses or for other medical or scientific purposes other than those currently proposed. Although pemetrexed has been shown to be effective in some patients with non-small-cell lung cancer, pemetrexed might not have beneficial effects for all patients.

Timeline

Start
2003-12
Primary completion
2006-10
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Pemetrexed Small molecule 900 mg/m2 Intravenous